AUTO 6 NG
Alternative Names: AUTO6 - Next Generation; AUTO6-NGLatest Information Update: 28 Jan 2025
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroblastoma; Osteosarcoma; Skin cancer; Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Neuroblastoma in United Kingdom (IV, Infusion)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (IV, Infusion)
- 03 Nov 2022 AUTO 6 NG is still in preclinical development phase for Neuroblastoma in United Kingdom (Autolus pipeline, January 2023)